Mark J. Cziraky

2.7k total citations
91 papers, 2.0k citations indexed

About

Mark J. Cziraky is a scholar working on Economics and Econometrics, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mark J. Cziraky has authored 91 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Economics and Econometrics, 37 papers in Surgery and 27 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mark J. Cziraky's work include Health Systems, Economic Evaluations, Quality of Life (43 papers), Lipoproteins and Cardiovascular Health (33 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (16 papers). Mark J. Cziraky is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (43 papers), Lipoproteins and Cardiovascular Health (33 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (16 papers). Mark J. Cziraky collaborates with scholars based in United States, Australia and United Kingdom. Mark J. Cziraky's co-authors include James M. McKenney, Benjamin M. Bluml, Vincent J. Willey, Terry A. Jacobson, Karol E. Watson, Robert L. Talbert, Jerome D. Cohen, Peter P. Tóth, Ralph Quimbo and James P. Guevara and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Mark J. Cziraky

88 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark J. Cziraky United States 25 769 533 482 432 317 91 2.0k
Karen A. Grace United States 10 584 0.8× 281 0.5× 479 1.0× 400 0.9× 426 1.3× 15 1.5k
Ana Filipa Macedo Portugal 14 970 1.3× 530 1.0× 460 1.0× 449 1.0× 177 0.6× 20 2.1k
Adam P. Bress United States 26 294 0.4× 315 0.6× 386 0.8× 1.5k 3.5× 173 0.5× 130 2.5k
Susanna M. Wallerstedt Sweden 28 771 1.0× 264 0.5× 145 0.3× 360 0.8× 524 1.7× 128 3.1k
Ariela R. Orkaby United States 24 497 0.6× 510 1.0× 235 0.5× 672 1.6× 902 2.8× 120 2.1k
Arja Helin‐Salmivaara Finland 19 382 0.5× 375 0.7× 98 0.2× 285 0.7× 175 0.6× 37 1.4k
Judy A. Staffa United States 19 301 0.4× 204 0.4× 108 0.2× 367 0.8× 166 0.5× 37 2.3k
Ettore Ambrosioni Italy 28 448 0.6× 262 0.5× 654 1.4× 2.6k 6.1× 183 0.6× 117 3.2k
Ida Fortino Italy 24 122 0.2× 280 0.5× 275 0.6× 450 1.0× 337 1.1× 108 1.9k
Adriaan M. Kamper Netherlands 17 2.0k 2.5× 771 1.4× 821 1.7× 826 1.9× 201 0.6× 26 3.2k

Countries citing papers authored by Mark J. Cziraky

Since Specialization
Citations

This map shows the geographic impact of Mark J. Cziraky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Cziraky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Cziraky more than expected).

Fields of papers citing papers by Mark J. Cziraky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Cziraky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Cziraky. The network helps show where Mark J. Cziraky may publish in the future.

Co-authorship network of co-authors of Mark J. Cziraky

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Cziraky. A scholar is included among the top collaborators of Mark J. Cziraky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Cziraky. Mark J. Cziraky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hoffman, Sarah R., Stephan Lanes, Jeff White, et al.. (2025). Comparative Safety of Glucagon‐Like Peptide 1 Receptor Agonists ( GLP ‐1‐ RAs ) in Type 2 Diabetes and Chronic Weight Management: A Real‐World Data Study. Pharmacoepidemiology and Drug Safety. 34(9). e70214–e70214.
2.
3.
Menard, Matthew T., Michael R. Jaff, Alik Farber, et al.. (2023). Baseline modern medical management in the BEST-CLI trial. Journal of Vascular Surgery. 78(3). 711–718.e5. 15 indexed citations
4.
Haynes, Kevin, Nandini Selvam, & Mark J. Cziraky. (2016). Bidirectional Data Collaborations in Distributed Research. SHILAP Revista de lepidopterología. 4(2). 1–1. 9 indexed citations
5.
Tóth, Peter P., Michael Grabner, Rajeshwari Punekar, et al.. (2014). Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis. 235(2). 585–591. 48 indexed citations
6.
Wasser, Thomas, Bingcao Wu, J. Ycas, Ozgur Tunceli, & Mark J. Cziraky. (2013). Establishing a weighting methodology to compute the number of patients with disease using claims data and census population in the united states. Value in Health. 16(3). A23–A23. 1 indexed citations
7.
Willke, Richard J., William H. Crown, Michael del Aguila, et al.. (2013). Melding Regulatory, Pharmaceutical Industry, and U.S. Payer Perspectives on Improving Approaches to Heterogeneity of Treatment Effect in Research and Practice. Value in Health. 16(6). S10–S15. 5 indexed citations
8.
Wei, Wenhui, Erin Buysman, Lee Brekke, et al.. (2013). The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy. Advances in Therapy. 30(12). 1128–1140. 21 indexed citations
9.
Wasser, Thomas, Bingcao Wu, J. Ycas, Ozgur Tunceli, & Mark J. Cziraky. (2013). Comparison of commercial insurance databases to census data for age, gender and geographic region in the united states. Value in Health. 16(3). A22–A23. 4 indexed citations
10.
Jacobson, Terry A., Debra Wertz, Andreas Kuznik, & Mark J. Cziraky. (2013). Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. Current Medical Research and Opinion. 29(7). 773–781. 2 indexed citations
11.
Tóth, Peter P., et al.. (2012). The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 11(1). 109–109. 72 indexed citations
12.
Kamat, Siddhesh, Michael Bullano, Chun‐Lan Chang, Sanjay Gandhi, & Mark J. Cziraky. (2011). Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population. Current Medical Research and Opinion. 27(5). 961–968. 29 indexed citations
13.
Yood, Marianne Ulcickas, Gerald N. DeLorenze, Charles P. Quesenberry, et al.. (2010). Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiology and Drug Safety. 19(11). 1124–1130. 16 indexed citations
14.
Cohen, Jerome D., Mark J. Cziraky, Qian Cai, et al.. (2010). 30-Year Trends in Serum Lipids Among United States Adults: Results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006. The American Journal of Cardiology. 106(7). 969–975. 123 indexed citations
15.
Malone, Daniel C., Trent P. McLaughlin, Peter Wahl, et al.. (2009). Burden of Alzheimer's disease and association with negative health outcomes.. PubMed. 15(8). 481–8. 42 indexed citations
16.
Barron, John J., et al.. (2009). HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment. The Oncologist. 14(8). 760–768. 26 indexed citations
17.
Balkrishnan, Rajesh, Michael Pollack, Vijay N. Joish, et al.. (2009). An economic evaluation of therapeutic alteration in the management of insomnia. Current Medical Research and Opinion. 25(3). 663–669. 3 indexed citations
18.
19.
Charland, Scott L., Mark J. Cziraky, Ralph Quimbo, et al.. (2008). Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. Journal of clinical lipidology. 2(5). 343–353. 6 indexed citations
20.
Cziraky, Mark J.. (2004). Management of Dyslipidemia in Patients with Metabolic Syndrome. Journal of the American Pharmacists Association. 44(4). 478–490. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen A. Grace Breakdown of academic impact, for papers by Ana Filipa Macedo Breakdown of academic impact, for papers by Adam P. Bress Breakdown of academic impact, for papers by Susanna M. Wallerstedt Breakdown of academic impact, for papers by Ariela R. Orkaby Breakdown of academic impact, for papers by Arja Helin‐Salmivaara Breakdown of academic impact, for papers by Judy A. Staffa Breakdown of academic impact, for papers by Ettore Ambrosioni Breakdown of academic impact, for papers by Ida Fortino Breakdown of academic impact, for papers by Adriaan M. Kamper
Rankless by CCL
2026